Ref. Ares(2022)2040969 - 21/03/2022
Meeting note 
 
Brief call with Sanofi on the health industrial ecosystem, 3 February 2022, 10:00-10:30 
Sanofi:
 
COM: Maurits-Jan Prinz (Cabinet of Commissioner Breton) 
 was also invited, but 
could not join) 
-  Sanofi presented its views in relation to the strategic autonomy of the health industry, referring to a 
recent article: https://confrontations.org/wp-content/uploads/2022/02/05-133.pdf. It highlighted its 
activities in the field of cell and gene therapy (which Sanofi described as addressing a major unmet 
medical need, while also involving a relatively high level of commercial risk), as well as its activities 
in the field of mRNA technology. Sanofi pointed out that some MS are actively investing in 
additional capacity (e.g.: https://www.bmwi.de/Redaktion/EN/Pressemitteilungen/2022/20220101-
funding-launched-for-speciality-lipids-used-as-key-components-of-mrna-vaccines.html). Sanofi 
referred to the plans for an Important Project of Common European Interest (IPCEI) in the health 
sector. COM stressed that it is up to Member States to determine the scope of an IPCEI and to 
identify relevant projects. Italy is the latest Member State to launch a call for project in this context: 
https://www.mise.gov.it/index.php/en/202-news-english/2043151-call-for-ipcei-on-health-now-open.  
-  Sanofi commented on the Commission’s Industry Forum, which was established under the revised 
Industry Strategy. Sanofi considered it important that the forum also captures experience from 
companies with an EU manufacturing presence (rather than only associations). Sanofi referred to the 
framework of sector strategic committees (“comités stratégiques de filière”) in France. The work of 
this committee could also be relevant in the context of the Commission’s Structured Dialogue on the 
security of medicines supply. COM asked Sanofi to share further information about this in writing. 
 
1 of 1 
 

---